ArticleACS omega2026
Integrating Molecular Modeling and Nanoemulsion Characterization for Ibuprofen.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibuprofen (IBU), a widely used nonsteroidal anti-inflammatory drug, exhibits low aqueous solubility and polymorphic behavior, which can compromise its bioavailability and pharmaceutical performance. This study investigated the structural, electronic, and supramolecular properties of two polymorphic forms of IBU and assessed their influence on the development and performance of emulsion-based delivery systems. The solid-state description included Hirshfeld surface analysis and the quantum theory of atoms in molecules complemented by density functional theory and electronic reactivity descriptors. Two formulations, an emulsion (EM-IBU) and a nanoemulsion (NE-IBU), were prepared and characterized by droplet size, polydispersity index, zeta potential, density, and drug content via mass spectrometry. Compared to EM-IBU, NE-IBU exhibited a considerably smaller particle size (31.3 ± 0.3 nm vs 235.4 ± 4.3 nm), a lower polydispersity index (0.23 vs 0.16), a more negative zeta potential (-25.8 vs -22.1 mV), and a higher density (0.989 vs 0.967 g cm
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.